| LSS . | 1 minute

MGB Biopharma receives funding of £2.78m from Innovate UK

A biopharmaceutical company developing novel anti-infectives has been awarded a £2.78 million grant to take forward clinical trials of a treatment discovered at the University of Strathclyde.

The grant will help fund a Phase IIa trial of the oral formulation of MGB Biopharma’s lead investigational drug candidate, MGB-BP-3, for the treatment of the Clostridium difficile infection. Approximately 30 patients are expected to be enrolled into the multi-centre trial to determine the safety, tolerability, dosing schedule and efficacy of ascending doses of the treatment.

To read the full article, click here.

Back to News

Do you have news for the Scottish Life Sciences Community?

Submit Your Own News
Top